Preliminary evaluation on the beneficial effects of pioglitazone in the treatment of endometrial cancer.
Garikapati Kusuma KumariAmmu V V V Ravi KiranPraveen Thaggikuppe KrishnamurthyPublished in: Medical oncology (Northwood, London, England) (2021)
Endometrial cancer (EMC) is one of the complicated gynecological cancers, affecting more than three million women worldwide. Anticancer strategies such as chemotherapy, radiation, and surgery are found to be ineffective and are associated with patient incompliances. The aim of the present study is to repurpose non-oncological drug, i.e., Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, in the treatment of endometrial cancer. The study groups consist of 50 female Swiss albino mice, out of which 40 had endometrial cancer induced with N-ethyl-N-nitrosourea (ENU) and estradiol hexadrobenzoate (EHB). The other groups received saline, EHB, paclitaxel, and different test doses of pioglitazones. Different preliminary parameters such as weekly body weight, mean survival time, percentage increase in life span, and uterine tissue weight were analyzed along with histopathological analysis. We observed a significant change in weekly body weight, improvement in percentage life span, and partial restoration of uterine tissue weight to normal compared to a standard drug, paclitaxel. In the present preliminary evaluation, we have identified that pioglitazone exhibited a significant dose-dependent anticancer activity against ENU- and EHB-induced endometrial cancer, compared to the standard paclitaxel.
Keyphrases
- endometrial cancer
- body weight
- physical activity
- high glucose
- body mass index
- drug induced
- weight loss
- squamous cell carcinoma
- prostate cancer
- polycystic ovary syndrome
- pregnant women
- insulin resistance
- locally advanced
- young adults
- type diabetes
- atrial fibrillation
- binding protein
- radiation therapy
- acute coronary syndrome
- adverse drug
- high fat diet induced
- endothelial cells
- combination therapy